Lv1
20 积分 2023-02-19 加入
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
11天前
已完结
https://www.nature.com/articles/s42255-024-01105-9
2个月前
已完结
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
3个月前
已完结
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities
5个月前
已完结
Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer
6个月前
已完结
Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer
7个月前
已完结
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
8个月前
已完结
Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?
8个月前
已完结
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer
8个月前
已完结
Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance
8个月前
已完结
皖公网安备34019202002308
